Class summary at a glance.

Every drug in the Cytochrome P450 17A1 Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $1.02Bcombined across class
Total Rx claims: 612K105K unique beneficiaries
Generic mfrs (active): 12across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Abiraterone

Brand: Abiraterone · 612K Part D claims (CY24) · 105K beneficiaries · First FDA approval: 2011-04-28

12 generic mfrs 942 plans require PA

Low NADAC$0.832

→

Avg plan cost$1.81

Part D spend $1.02B 2× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.